Emicizumab|cas:1610943-06-0|西域试剂

Emicizumab

产品编号：Bellancom-P9940| CAS NO：1610943-06-0

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P9940		￥27000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Emicizumab

产品介绍

Emicizumab 是一种双特异性单克隆抗体，连接激活因子 IX 和激活因子 X，取代缺失的激活因子 VIII 的功能，从而恢复止血。Emicizumab 可用于血友病 A 研究。

生物活性

Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.

体外研究

体内研究

Emicizumab (1.5-10 mg/kg，静脉注射，尾夹出血前 24 小时)部分纠正血友病a型出血模型中的失血，FVIII 等效为 9 U/dL。
Emicizumab (3 mg /kg, 静脉注射) 联合低剂量 FVIII (10 U/dL) 时可提供额外的止血活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	FVIII-deficient mice
Dosage:	1.5-10 mg/kg
Administration:	IV, 24 hours before tail-clip bleeding was performed
Result:	Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	FVIII-deficient mice
Dosage:	1.5-10 mg/kg
Administration:	IV, 24 hours before tail-clip bleeding was performed
Result:	Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice.